Medicare Enrolled
Dr. Abhisek Swaika, MBBS
Hematology & Oncology · Fresh Meadows, NY
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Swaika from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Swaika?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Swaika
Dr. Abhisek Swaika is a hematology & oncology specialist in Fresh Meadows, NY, with 16 years of NPI registration. Based on federal Medicare data, Dr. Swaika performed 25,907 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Swaika received a total of $234,084 from 21 pharmaceutical and/or device companies across 316 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Swaika is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years of NPI registration
▲ Top 18% volume in NY
$234,084 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗25,907
Medicare services
Top 18% in NY for hematology & oncology
Not available
Unique patients (not deduplicated)
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) An injection of iron sucrose used to replenish iron levels in the body. |
11,400 | $0 | $1 |
| Denosumab injection (Prolia/Xgeva) | 6,240 | $18 | $57 |
| Epoetin alfa injection (Procrit) for anemia An injection of epoetin alfa containing 1000 units for use in patients not on end-stage renal disease (ESRD) dialysis. |
2,080 | $6 | $37 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
1,018 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
918 | $8 | $17 |
| Anti-nausea injection (Aloxi/palonosetron) | 860 | $1 | $67 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
825 | $8 | $44 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
671 | $114 | $475 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
366 | $15 | $134 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
315 | $127 | $952 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
253 | $13 | $115 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
237 | $63 | $391 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
117 | $78 | $383 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
90 | $27 | $210 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
86 | $1 | $2 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
84 | $74 | $322 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
81 | $162 | $641 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
74 | $28 | $192 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
54 | $12 | $93 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
33 | $2 | $8 |
| Initial hospital admission, moderate complexity Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter. |
30 | $122 | $605 |
| New patient office visit, complex (60-74 min) | 23 | $208 | $919 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
23 | $159 | $879 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
17 | $139 | $736 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
12 | $54 | $405 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
2.5% high complexity
86.4% medium
11.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$234,084
Total received (2018-2024)
Avg $33,441/year across 7 years
Top 4% in NY for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
21
Companies
316
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$3,312
2023
$3,628
2022
$13,054
2021
$11,412
2020
$12,394
2019
$125,768
2018
$64,516
Payments by company (2024)
Exelixis Inc.
$1,715
PFIZER INC.
$1,354
Rigel Pharmaceuticals, Inc.
$124
AstraZeneca Pharmaceuticals LP
$118
Top 3 companies account for 96.4% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$99,787
Rigel Pharmaceuticals, Inc.
$92,634
Celgene Corporation
$8,139
AbbVie, Inc.
$5,658
PFIZER INC.
$5,359
Puma Biotechnology, Inc.
$3,883
EISAI INC.
$3,535
Exelixis Inc.
$3,306
ABBVIE INC.
$3,025
Janssen Scientific Affairs, LLC
$2,722
Incyte Corporation
$2,185
GlaxoSmithKline, LLC.
$1,840
Seattle Genetics, Inc.
$1,691
Takeda Pharmaceuticals U.S.A., Inc.
$145
Lexicon Pharmaceuticals, Inc.
$46
E.R. Squibb & Sons, L.L.C.
$35
Novartis Pharmaceuticals Corporation
$25
Mirati Therapeutics, Inc.
$21
Bayer HealthCare Pharmaceuticals Inc.
$19
Tactile Systems Technology Inc
$14
Verastem, Inc.
$14
Top 3 companies account for 85.7% of all-time payments
Associated products mentioned in payments ›
Abraxane · CABOMETYX · CALQUENCE · Cabometyx · Copiktra · DARZALEX · Erleada · FLEXITOUCH · Fedratinib · IMFINZI · INREBIC · KRAZATI · Lenvima · NINLARO · Nerlynx · OPDIVO · ORGOVYX · PIQRAY · Rezlidhia · TAGRISSO · TIVDAK · Tavalisse · VENCLEXTA · Venclexta · Vitrakvi · XTANDI · Xermelo
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Hematology & oncology specialists in nearby ZIP areas
693
County median income
$84,961
Nearest hospital to ZIP centroid (approximate)
QUEENS HOSPITAL CENTER
1.3 mi
1.3 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Swaika is a mixed practice specialist, with above-average Medicare volume (top 18% in NY), with 16 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Swaika experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Swaika performed 11,400 iron sucrose injection (venofer) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Swaika receive payments from pharmaceutical companies?
Yes. Dr. Swaika received a total of $234,084 from 21 companies across 316 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Swaika's costs compare to other hematology & oncology specialists in Fresh Meadows?
Dr. Swaika's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Swaika) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Fresh Meadows
Browse hematology & oncology specialists in Fresh Meadows ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in NY
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in NY
Which NY hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
Rigel Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Rigel Pharmaceuticals, Inc.
By company
Celgene Corporation Payments to Doctors
See all physicians who received payments from Celgene Corporation.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology